Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 16, 2020
BioNTech and Shanghai Fosun Pharmaceutical today announced an agreement to supply Mainland China with 100 million doses initially of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval.
Lead Product(s): Bulevirtide Acetate
Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,762.0 million Upfront Cash: $1,400.0 million
Deal Type: Acquisition December 10, 2020
The acquisition will provide Gilead with Hepcludex™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.